Publication | Closed Access

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

MalariaImmunologyParasite GenomicsMalaria-naïve AdultsEscalation SafetyMedicineImmunogenicity TrialParasitology